<DOC>
	<DOCNO>NCT01240863</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy hydrocodone extended-release tablet compare placebo alleviate moderate severe pain patient osteoarthritis low back pain assess weekly Average Pain Intensity ( API ) week 12 .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Hydrocodone Bitartrate Extended-Release Tablets ( CEP-33237 ) Relief Moderate Severe Pain Patients With Osteoarthritis Low Back Pain Who Require Opioid Treatment Extended Period Time</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>The patient able speak English willing provide write informed consent , include write opioid agreement , participate study . The patient must willing able successfully selfadminister study drug , comply study restriction , complete electronic diary , return clinic schedule study visit specify protocol . Women childbearing potential ( surgically sterile 2 year postmenopausal ) , must use medically accept method contraception must agree continue use method duration study 30 day participation study , negative pregnancy test screening . The patient pain least 3 month ' duration associate osteoarthritis low back pain . The patient report average pain intensity score , prior 24 hour , 5 NRS11 . If patient receive physical therapy , biofeedback therapy , acupuncture therapy , herbal remedy , therapy must remain unchanged study . The patient must participate study involve investigational agent enrol present study . The patient know suspected hypersensitivity , allergy , contraindication ingredient study drug . The patient recent history ( within 5 year ) current evidence alcohol substance abuse exception nicotine caffeine . The patient medical psychiatric disease , opinion investigator , would compromise collect data . The patient take total ( ie , aroundtheclock plus rescue medication ) 135 mg/day oxycodone , equivalent , 14 day prior screen . The patient history suicidality . The patient expect surgery study . The patient 's primary painful condition study relate source chronic pain osteoarthritis low back pain . The patient pregnant lactating . The patient active malignancy . The patient human immunodeficiency virus ( HIV ) . In judgment investigator , patient clinically significant deviation normal physical examination and/or clinical laboratory test value . The patient cardiopulmonary disease would , opinion investigator , significantly increase risk treatment opioids . The patient participate study involve investigational drug previous 30 day . The patient receive monoamine oxidase inhibitor ( MAOI ) within 14 day first treatment study drug . The patient medical condition receive concomitant medication/therapy ( e.g. , regional nerve block ) would , opinion investigator , compromise patient 's safety compliance study protocol , compromise collect data . The patient involve active litigation regard pain currently treat . The patient positive urine drug screen ( UDS ) medically explainable . The investigator feels patient suitable study reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>low back pain</keyword>
	<keyword>Moderate Severe Pain</keyword>
</DOC>